

CADTH Reference List

# Switching From Reference to Biosimilar Insulin Aspart for Patients With Diabetes Mellitus (Type 1 or Type 2)

November 2021

**Authors:** Camille Santos, Carolyn Spry

**Cite As:** Switching from reference to biosimilar insulin aspart for patients with diabetes mellitus (Type 1 or 2). (CADTH reference list: summary of abstracts). Ottawa: CADTH; 2021 Nov.

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to [requests@cadth.ca](mailto:requests@cadth.ca)

## Key Message

- Two randomized controlled trials were identified regarding the clinical effectiveness of switching from reference to biosimilar insulin aspart in adult or pediatric patients with diabetes mellitus (Type 1 or Type 2).

## Research Question

What is the clinical effectiveness of switching from reference to biosimilar insulin aspart in adult or pediatric patients with diabetes mellitus (Type 1 or Type 2)?

## Methods

### Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were reference insulin aspart and biosimilars. No search filters were applied to limit retrieval by study type. Conference abstracts were excluded. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2016 and November 1, 2021. Internet links were provided, where available.

### Selection Criteria and Summary Methods

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in Table 1. Full texts of study publications were not reviewed. The Overall Summary of Findings was based on information available in the abstracts of selected publications.

## Results

Two randomized controlled trials<sup>1,2</sup> were identified regarding the clinical effectiveness of switching from reference to biosimilar insulin aspart in adult or pediatric patients with diabetes mellitus (Type 1 or Type 2). No health technology assessments, systematic reviews, or non-randomized studies were identified.

Additional references of potential interest that did not meet the inclusion criteria are provided in Appendix 1.

**Table 1: Selection Criteria**

Criteria	Description
Population	Patients (any age) with diabetes mellitus (Type 1 or 2)
Intervention	Switching from reference insulin aspart (i.e., NovoRapid) to biosimilar insulin aspart (i.e., Trurapi)
Comparator	Continuous use of reference insulin aspart; pre/post switch comparisons
Outcomes	Effectiveness (e.g., change in disease severity, disease complications, health-related quality of life) and safety (e.g., adverse events, withdrawal due to adverse event)
Study designs	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies

## Overall Summary of Findings

Two randomized controlled trials were identified regarding the clinical effectiveness of switching from reference to biosimilar insulin aspart in adult or pediatric patients with diabetes mellitus (Type 1 or Type 2).<sup>1,2</sup> One open-label randomized controlled trial (i.e., GEMELLI 1 study) transitioned adult participants with diabetes (Type 1 or Type 2) from Novolog/NovoRapid insulin aspart (NN-Asp) or Humalog R/Liprolog R to either NN-Asp or biosimilar insulin aspart SAR341402 (SAR-Asp).<sup>1</sup> In a subgroup analysis of the GEMELLI 1 trial, no differences in hemoglobin A1C change, changes in insulin doses, hypoglycemia, and safety outcomes were found between those transitioned to SAR-Asp and NN-Asp at 26 and 52 weeks within the subgroup of patients originally receiving NN-Asp.<sup>1</sup> An open-label crossover trial randomized adult patients with type 1 diabetes to a self-administered treatment sequence of SAR-Asp to NN-Asp or SAR-Asp NN-Asp through an insulin pump.<sup>2</sup> Both treatments were well tolerated by patients, with no significant difference in infusion set occlusions over a 4-week treatment period.<sup>2</sup> Additionally, no differences in hypoglycemia, adverse events, hypersensitivity, and injection site reactions were detected between treatments.<sup>2</sup>

## References

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-analyses

No literature identified.

### Randomized Controlled Trials

1. Shah VN, Franek E, Wernicke-Panten K, Pierre S, Mukherjee B, Sadeharju K. Efficacy, safety, and immunogenicity of insulin aspart biosimilar SAR341402 compared with originator insulin aspart in adults with diabetes (GEMELLI 1): a subgroup analysis by prior type of mealtime insulin diabetes therapy research, treatment and education of diabetes and related disorders. *Diabetes Ther.* Feb 2021; 12(2): 557-568. [PubMed](#)
2. Thrasher J, Polsky S, Hovsepian L, et al. Safety and tolerability of insulin aspart biosimilar SAR341402 versus originator insulin aspart (NovoLog) when used in insulin pumps in adults with Type 1 diabetes: a randomized, open-label clinical trial. *Diabetes Technol Ther.* 09 2020; 22(9): 666-673. [PubMed](#)

### Non-Randomized Studies

No literature identified.

## Appendix 1: References of Potential Interest

### Randomized Controlled Trials

#### *Alternative Comparator – Not Switching*

3. Karonova TL, Mayorov AY, Magruk MA, et al. Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid R Penfill R) in Type 1 diabetes mellitus. *J Comp Eff Res*. 06 2021; 10(9): 763-775. [PubMed](#)
4. Garg SK, Wernicke-Panten K, Wardecki M, et al. Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes treated for 26 weeks with multiple daily injections in combination with insulin glargine: a randomized open-label trial (GEMELLI 1). *Diabetes Technol Ther*. 02 2020; 22(2): 85-95. [PubMed](#)

#### *Intervention Not Specific to NovoRapid*

5. Garg SK, Wernicke-Panten K, Wardecki M, et al. Safety, immunogenicity, and glycemic control of insulin aspart biosimilar SAR341402 versus originator insulin aspart in people with diabetes also using insulin glargine: 12-month results from the GEMELLI 1 trial. *Diabetes Technol Ther*. 07 2020; 22(7): 516-526. [PubMed](#)